TLR9 Antibody (26C593R) [DyLight 550]
Novus Biologicals, part of Bio-Techne | Catalog # FAB36583L
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Intracellular Staining by Flow Cytometry
Label
DyLight 550 (Excitation = 562 nm, Emission = 576 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG1 Clone # 26C593R
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Antibody developed against the KLH-conjugated synthetic peptide corresponding to amino acids Asp250-Asn300 of human TLR9 isoform A.
Accession # Q9NR96
Accession # Q9NR96
Specificity
Detects human TLR9 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for TLR9 Antibody (26C593R) [DyLight 550]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Intracellular Staining by Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: TLR9
Long Name
Toll-like Receptor 9
Alternate Names
CD289
Additional TLR9 Products
Product Documents for TLR9 Antibody (26C593R) [DyLight 550]
Product Specific Notices for TLR9 Antibody (26C593R) [DyLight 550]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...